280 related articles for article (PubMed ID: 12380158)
1. [Tenofovir in Study 903. Also effective and tolerable in first-line therapy].
MMW Fortschr Med; 2002 Aug; 144(33-34):61. PubMed ID: 12380158
[No Abstract] [Full Text] [Related]
2. [First nucleotide analog against HIV. Lowers viral load also in drug resistance].
MMW Fortschr Med; 2002 Aug; 144(33-34):60-1. PubMed ID: 12380157
[No Abstract] [Full Text] [Related]
3. New uses for tenofovir: more questions about d4T.
Proj Inf Perspect; 2003 Jan; (35):15-6. PubMed ID: 12647676
[TBL] [Abstract][Full Text] [Related]
4. [Tenofovir (Viread)].
Sidahora; 2002; (1):20-1. PubMed ID: 12772661
[No Abstract] [Full Text] [Related]
5. Tenofovir--long term results from first-line therapy.
TreatmentUpdate; 2003; 15(2):4-6. PubMed ID: 12693361
[No Abstract] [Full Text] [Related]
6. [96-week treatment outcome confirms long term efficacy of tenofovir DF].
Dtsch Med Wochenschr; 2003 May; 128(19):1074-5. PubMed ID: 12774796
[No Abstract] [Full Text] [Related]
7. Tenofovir: FDA hearing October 3, public comment deadlines September 26.
James JS
AIDS Treat News; 2001 Aug; (370):3-4. PubMed ID: 11570163
[No Abstract] [Full Text] [Related]
8. Tenofovir drug interactions: ddI and d4T.
TreatmentUpdate; 2003; 15(2):7. PubMed ID: 12693363
[No Abstract] [Full Text] [Related]
9. The potential place of tenofovir in antiretroviral treatment regimens.
Gazzard BG
Int J Clin Pract; 2001 Dec; 55(10):704-9. PubMed ID: 11777298
[TBL] [Abstract][Full Text] [Related]
10. Tenofovir: FDA hearing on important new antiretroviral.
James JS
AIDS Treat News; 2001 Oct; (372):2-4. PubMed ID: 11702411
[No Abstract] [Full Text] [Related]
11. Tenofovir disoproxil fumarate.
Gallant JE; Deresinski S
Clin Infect Dis; 2003 Oct; 37(7):944-50. PubMed ID: 13130407
[TBL] [Abstract][Full Text] [Related]
12. Promising results for tenofovir.
AIDS Patient Care STDS; 2000 Jul; 14(7):396. PubMed ID: 10935058
[No Abstract] [Full Text] [Related]
13. [No comparison with NRTI. Tenofovir is robust against resistance trouble].
MMW Fortschr Med; 2002 Apr; 144 Suppl 1():65. PubMed ID: 12043079
[No Abstract] [Full Text] [Related]
14. 96-week CASTLE data show similar efficacy results.
AIDS Patient Care STDS; 2008 Nov; 22(11):918. PubMed ID: 19043840
[No Abstract] [Full Text] [Related]
15. Tenofovir DF on the horizon. Investigational nucleotide reverse transcriptor inhibitor could be on pharmacy shelves soon.
Eagan L
Posit Living; 2001; 10(5):21. PubMed ID: 11693102
[No Abstract] [Full Text] [Related]
16. [First nucleotide analog on the market. New drug for the pretreated patient].
MMW Fortschr Med; 2002 Apr; 144 Suppl 1():84. PubMed ID: 12043094
[No Abstract] [Full Text] [Related]
17. French investigators warn of LPV/TDF/ddI interaction.
Carter M
IAPAC Mon; 2003 Dec; 9(12):315. PubMed ID: 15055164
[No Abstract] [Full Text] [Related]
18. Use of tenofovir.
AIDS Patient Care STDS; 2002 Jan; 16(1):52. PubMed ID: 11892609
[No Abstract] [Full Text] [Related]
19. [First line therapy. Tenofovir DF/emtricitabine--the potent backbone].
MMW Fortschr Med; 2008 Apr; 150 Spec No 1():12-4. PubMed ID: 19024908
[No Abstract] [Full Text] [Related]
20. Marked elevation of the creatine phosphokinase level in a patient receiving tenofovir.
Shere-Wolfe KD; Verley JR
Clin Infect Dis; 2002 Nov; 35(9):1137. PubMed ID: 12384851
[No Abstract] [Full Text] [Related]
[Next] [New Search]
